Lecanemab blood biomarkers may rebound much faster than amyloid PET after treatment stops: a 2026 PK/PD model estimated that half of the Aβ42/40 treatment effect is lost within 0.5 years, compared with 12.1 years for amyloid PET signal.1 Research Highlights 0.5-year rebound for Aβ42/40: Bhagunde et al. estimated that half of the Aβ42/40 treatment effect …
A 2026 multi-cohort Alzheimer’s disease study found that MRI radiomics from the hippocampus and amygdala linked plasma pTau217 and smell identification to cognitive impairment — with more added cognitive signal than simple regional volume. The result is useful because it points to a possible bridge between blood biomarkers and brain-circuit damage, but it is still …
A 2026 medRxiv case-control study found that serum myelin oligodendrocyte glycoprotein was 20.5 pg/ml higher in multiple sclerosis than in healthy donors and 15.3 pg/ml higher during relapse than remission, making it a plausible blood marker of demyelination rather than a replacement for neurofilament light chain. Research Highlights MOG was higher in MS: serum myelin …
Schizophrenia (SZ) is a complex psychiatric disorder characterized by a myriad of symptoms, typically divided into positive, negative, and cognitive categories. Despite the prevalence and severity of this condition, current diagnostic methods are largely based on subjective clinical interviews and observations, leading to potential misdiagnosis and delayed treatment. Recent studies have focused on microRNAs (miRNAs) …
Attention-deficit/hyperactivity disorder (ADHD) is a common childhood-onset neurodevelopmental disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity. While highly heritable, the heterogeneity of clinical presentation suggests complex interactions between genetic and environmental risk factors. A new study suggests that it may be possible to diagnose ADHD or detect ADHD susceptibility risk in children …